Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
97.45 EUR | +0.05% | +1.35% | -5.39% |
Apr. 26 | Arkema: BlackRock holds less than 5% of the capital | CF |
Apr. 18 | Arkema to Acquire Majority Stake in Austria's Proionic | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.39% | 7.81B | C+ | ||
+4.67% | 103B | A- | ||
+2.40% | 68.41B | A- | ||
+42.86% | 39.97B | B | ||
+16.96% | 38.97B | B | ||
+6.96% | 33.12B | A- | ||
+7.89% | 19.41B | B- | ||
+12.12% | 16.73B | C+ | ||
+12.08% | 15.34B | B | ||
+17.69% | 15.07B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AKE Stock
- Ratings Arkema